- Home
- YSG vs NMRA Comparison
YSG vs NMRA Comparison
Compare YSG & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YSG | NMRA |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.7M | 311.3M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | YSG | NMRA |
|---|---|---|
| Price | $3.30 | $1.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 103.3K | ★ 1.5M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.08 | N/A |
| Revenue Next Year | $9.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $0.83 |
| 52 Week High | $10.59 | $3.65 |
Technical Indicators
Market Signals| Indicator | YSG | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 42.24 |
| Support Level | $3.01 | $0.83 |
| Resistance Level | $3.47 | $1.72 |
| Average True Range (ATR) | 0.25 | 0.10 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 16.81 | 9.09 |
Price Performance
Historical ComparisonAbout YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands. Geographically, company operates in PRC, Europe and US regions.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.